Copyright
©The Author(s) 2020.
World J Gastroenterol. Aug 28, 2020; 26(32): 4846-4856
Published online Aug 28, 2020. doi: 10.3748/wjg.v26.i32.4846
Published online Aug 28, 2020. doi: 10.3748/wjg.v26.i32.4846
Variable | Univariate analysis | Multivariate analysis | |||||
OR | 95%CI | P value | OR | 95%CI | P value | ||
Gender | Male | 1 (Reference) | |||||
Female | 1.202 | 0.998-1.447 | 0.052 | ||||
Age | 1.018 | 1.011-1.024 | < 0.001 | 1.014 | 1.008-1.021 | < 0.001 | |
Eradication attempts | Primary | 1 (Reference) | 1 (Reference) | ||||
Rescue | 1.816 | 1.432-2.302 | < 0.001 | 1.538 | 1.179-2.007 | 0.002 | |
Antibiotic regimens | Amoxicillin plus clarithromycin | 1 (Reference) | 1 (Reference) | ||||
Amoxicillin plus levofloxacin | 1.347 | 0.761-2.385 | 0.306 | 1.167 | 0.654-2.084 | 0.601 | |
Amoxicillin plus furazolidone | 1.314 | 0.701-2.461 | 0.394 | 0.982 | 0.505-1.911 | 0.958 | |
Clarithromycin plus metronidazole | 4.179 | 2.928-5.966 | < 0.001 | 3.139 | 2.125-4.637 | < 0.001 | |
Clarithromycin plus levofloxacin | 1.958 | 1.599-2.397 | < 0.001 | 1.863 | 1.517-2.287 | < 0.001 | |
Clarithromycin plus furazolidone | 6.4 | 3.200-12.797 | < 0.001 | 5.748 | 2.834-11.655 | < 0.001 | |
Levofloxacin plus furazolidone | 2.947 | 1.147-7.574 | 0.025 | 2.115 | 0.798-5.605 | 0.132 | |
PPIs | Esomeprazole | 1 (Reference) | 1 (Reference) | ||||
Rabeprazole | 1.168 | 0.909-1.502 | 0.225 | 1.138 | 0.879-1.473 | 0.327 | |
Lansoprazole | 1.197 | 0.614-2.332 | 0.598 | 1.262 | 0.638-2.496 | 0.504 | |
Pantoprazole | 1.509 | 1.161-1.961 | 0.002 | 1.398 | 1.067-1.831 | 0.015 | |
Omeprazole | 1.963 | 1.482-2.600 | < 0.001 | 1.513 | 1.113-2.056 | 0.008 |
- Citation: Yan TL, Gao JG, Wang JH, Chen D, Lu C, Xu CF. Current status of Helicobacter pylori eradication and risk factors for eradication failure. World J Gastroenterol 2020; 26(32): 4846-4856
- URL: https://www.wjgnet.com/1007-9327/full/v26/i32/4846.htm
- DOI: https://dx.doi.org/10.3748/wjg.v26.i32.4846